Abstract
Cutaneous adverse events (AEs) are frequent with systemic melanoma treatments. As a result of a paradigmatic shift in melanoma management from traditional cytotoxic chemotherapy to immunotherapies and targeted therapies as first-line treatment, the spectrum of skin AEs to these treatments has significantly broadened. Cutaneous toxicities from anticancer therapy manifest as doubly burdensome as visible stigmatization often carries profound psychosocial implications. Early detection and treatment help to minimize a reduction in patients’ quality of life and maximize anticancer treatment adherence and outcome. The knowledge of typical presentations associated with the specific drug regimen administered to the patient is essential for timely management of these conditions. A dermatological evaluation of the skin condition appears to be essential for an interdisciplinary approach as very often even dramatic skin presentations do not necessitate a cessation of the potentially lifesaving antineoplastic drug. Since the onset of AEs of some therapies can take up to several months or years and may also occur in cancer survivors long after completion of their therapy, thorough dermatological follow-up may be advised even after successful completion of antineoplastic treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Atopic dermatitis
- ADLs:
-
Activities of daily living
- AE:
-
Adverse event
- AH:
-
Antihistamines
- AK:
-
Actinic keratosis
- BP:
-
Bullous pemphigoid
- BPAG:
-
Bullous pemphigoid antigen
- BRAF wt:
-
BRAF wild-type mutation
- BRAFi:
-
BRAF inhibitor
- BSA:
-
Body surface area
- CIA:
-
Chemotherapy-induced alopecia
- CsA:
-
Cyclosporin A
- CTCAE:
-
Common Terminology Criteria for Adverse Events
- CTLA-4:
-
Cytotoxic T-lymphocyte antigen-4
- cuSCC/SCC:
-
(Cutaneous) Squamous cell carcinoma
- DEJ:
-
Dermo-epidermal junction
- DRESS:
-
Drug reaction with eosinophilia and systemic symptoms
- DTIC:
-
5-(3,3-Dimethyl-1-triazeno) imidazole-4-carboxamide
- EGFRi:
-
Epidermal growth factor receptor inhibitor
- FDA:
-
Food and Drug Administration
- H&E:
-
Hematoxylin and Eosin stain
- HDAC:
-
Histone deacetylase
- HFS:
-
Hand-foot syndrome
- ICI:
-
Immune checkpoint inhibitor
- IDO:
-
Indoleamine-pyrrole 2,3-dioxygenase
- ircAE:
-
Immune-related cutaneous adverse event
- irAE:
-
Immune-related adverse event
- KA:
-
Keratoacanthoma
- LP:
-
Lichen planus
- MAPK pathway:
-
Mitogen-activated protein kinase pathway
- MEKi:
-
MEK inhibitor
- MMF:
-
Mycophenolate mofetil
- MTIC:
-
5-3-Methyltriazen-1-yl-imidazo-4-carboxamide
- MTX:
-
Methotrexate
- NSCLC:
-
Non-small cell lung cancer
- OS:
-
Overall survival
- OTC:
-
Over-the-counter
- PD-1:
-
Programmed cell death protein-1
- PD-L1:
-
Programmed cell death ligand-1
- PFS:
-
Progression-free survival
- QoL:
-
Quality of life
- RCC:
-
Renal cell carcinoma
- RR:
-
Response rate
- SCAR:
-
Severe cutaneous adverse reaction
- SJS:
-
Stevens-Johnson syndrome
- TCR:
-
T-cell receptor
- TEN:
-
Toxic epidermolytic necrolysis
References
Amitay-Laish I, Stemmer SM, Lacouture ME (2011) Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 24:386–395. https://doi.org/10.1111/j.1529-8019.2011.01431.x
Anforth R, Fernandez-Penas P, Long GV (2013) Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14:e11–e18. https://doi.org/10.1016/S1470-2045(12)70413-8
Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Penas P (2015) Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol 172:239–243. https://doi.org/10.1111/bjd.13200
Arbour KC et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872–2878. https://doi.org/10.1200/JCO.2018.79.0006
Ascierto PA et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X
Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL (2011) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Investig New Drugs 29:1114–1121. https://doi.org/10.1007/s10637-010-9567-3
Barrios D, Ciccolini K, Phillips G, Skripnik Lucas A, Hsu M, Freites-Martinez A, Marchetti M, Deng L, Belum R, Lacouture ME (2017) Anti-cancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at Memorial Sloan Kettering cancer Center. Paper presented at the American Academy of Dermatology 75th annua meeting, Orlando, 3 Mar 2017
Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U (2013) Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol 9:1161–1170. https://doi.org/10.2217/fon.13.62
Berger TG, Steinhoff M (2011) Pruritus in elderly patients – eruptions of senescence. Semin Cutan Med Surg 30:113–117. https://doi.org/10.1016/j.sder.2011.04.002
Boussemart L et al (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149:855–857. https://doi.org/10.1001/jamadermatol.2013.4200
Camidge R, Price A (2001) Characterizing the phenomenon of radiation recall dermatitis. Radiol Oncol 59:237–245
Capriotti K, Capriotti J, Pelletier J, Stewart K (2017) Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. Cancer Manag Res 9:225–228. https://doi.org/10.2147/CMAR.S139301
Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. https://doi.org/10.1056/NEJMoa1103782
Chen S, Velez N, Saavedra A (2017) Adverse cutaneous drug reactions. In: McKean SRJ, Dressler D, Scheurer D (eds) Principles and practice of hospital medicine, vol 2. McGraw-Hill, New York, pp 1114–1124
Chirasuthat P, Chayavichitsilp P (2018) Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma. Case Rep Dermatol 10:198–202. https://doi.org/10.1159/000492172
Choi JN (2014) Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg 33:40–48
Chou S, Zhao C, Hwang SJE, Fernandez-Penas P (2017) PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases. J Cutan Pathol 44:851–856. https://doi.org/10.1111/cup.13013
Chu EY et al (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 67:1265–1272. https://doi.org/10.1016/j.jaad.2012.04.008
Coleman E, Panse G, Haldas J, Gettinger SN, Leventhal JS (2018) Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAAD Case Rep 4:669–671. https://doi.org/10.1016/j.jdcr.2018.06.022
Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125–128. https://doi.org/10.1016/j.currproblcancer.2016.12.001
Crosby T, Fish R, Coles B, Mason MD (2000) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev:CD001215. https://doi.org/10.1002/14651858.CD001215
Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147. https://doi.org/10.1056/NEJMoa050092
Dika E et al (2017) Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. Eur J Dermatol 27:266–270. https://doi.org/10.1684/ejd.2017.3023
Dummer R, Rinderknecht J, Goldinger SM (2012) Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 366:480–481. https://doi.org/10.1056/NEJMc1113752
Dummer R et al (2018a) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603–615. https://doi.org/10.1016/S1470-2045(18)30142-6
Dummer R et al (2018b) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/s1470-2045(18)30497-2
Dummer R et al (2018c) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1315–1327. https://doi.org/10.1016/S1470-2045(18)30497-2
Eggermont AMM et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789–1801. https://doi.org/10.1056/NEJMoa1802357
Enomoto Y, Nakatani H, Kondo S, Kasai T, Tsuchiya Y (2018) Drug-induced oral lichenoid reaction during nivolumab therapy. Int J Oral Maxillofac Surg. https://doi.org/10.1016/j.ijom.2018.07.025
Ensslin CJ, Rosen AC, Wu S, Lacouture ME (2013) Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 69:708–720. https://doi.org/10.1016/j.jaad.2013.06.038
Faje AT et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124:3706–3714. https://doi.org/10.1002/cncr.31629
Flaherty KT et al (2012a) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114. https://doi.org/10.1056/NEJMoa1203421
Flaherty KT et al (2012b) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703. https://doi.org/10.1056/NEJMoa1210093
Fontecilla NM, Kittler NW, Lopez A, Yang C, Geskin L (2018) Programmed cell death protein-1 inhibitor-induced granuloma annulare and hypertrophic lichen planus masquerading as squamous cell carcinoma. JAAD Case Rep 4:636–639. https://doi.org/10.1016/j.jdcr.2018.01.020
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136
Gelot P et al (2013) Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol 22:297–298. https://doi.org/10.1111/exd.12119
Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22:4023–4029. https://doi.org/10.1158/1078-0432.CCR-15-2872
Guo J et al (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904–2909. https://doi.org/10.1200/JCO.2010.33.9275
Habre M, Habre SB, Kourie HR (2016) Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy 8:1437–1446. https://doi.org/10.2217/imt-2016-0074
Hanley T, Papa S, Saha M (2018) Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma. JRSM Open 9. https://doi.org/10.1177/2054270418793029
Hassel JC et al (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003
Hauschild A et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet Lond Engl 380:358–365. https://doi.org/10.1016/S0140-6736(12)60868-X
Horvat TZ et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center. J Clin Oncol 33:3193–3198. https://doi.org/10.1200/JCO.2015.60.8448
Hua C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45–51. https://doi.org/10.1001/jamadermatol.2015.2707
Hwang SJ et al (2016) Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74:455–461 e451. https://doi.org/10.1016/j.jaad.2015.10.029
Hwang A, Iskandar A, Dasanu CA (2018) Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract. https://doi.org/10.1177/1078155218791314
Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y, Tomii K (2017) Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 109:58–61. https://doi.org/10.1016/j.lungcan.2017.04.020
Joly P et al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321–327. https://doi.org/10.1056/NEJMoa011592
Jour G et al (2016) Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 43:688–696. https://doi.org/10.1111/cup.12717
Keating GM (2016) Cobimetinib plus vemurafenib: a review in BRAF (V600) mutation-positive unresectable or metastatic melanoma. Drugs 76:605–615. https://doi.org/10.1007/s40265-016-0562-7
Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377–2385. https://doi.org/10.1093/annonc/mdx286
Kim KB et al (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482–489. https://doi.org/10.1200/JCO.2012.43.5966
Kunze J, Roeber H, Kollakowski M (1980) Phototoxic dermatitis caused by DTIC-treatment. Z Hautkr 55:100–101
Lacouture ME (2014) Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients, 1st edn. Wiley-Blackwell, Philadelphia
Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. https://doi.org/10.1007/s40257-018-0384-3
Lacouture ME et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357. https://doi.org/10.1200/JCO.2008.21.7828
Lacouture ME et al (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18:314–322. https://doi.org/10.1634/theoncologist.2012-0333
Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A (2014) Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 71:161–169. https://doi.org/10.1016/j.jaad.2014.02.035
Lacouture ME, Wu J, Markova A (2019) Dermatologic adverse events from cancer treatments. In: Shear N, Dodiuk-Gad R (eds) Advances in diagnosis and management of cutaneous adverse drug reactions. Springer Nature Singapore, Singapore. https://doi.org/10.1007/978-981-13-1489-6_10
Larkin J et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/NEJMoa1504030
Levy A, Guitera P, Kerob D, Ollivaud L, Archimbaud A, Dubertret L, Basset-Seguin N (2006) Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma. Ann Dermatol Venereol 133:157–160
Long GV et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet Lond Engl 386:444–451. https://doi.org/10.1016/S0140-6736(15)60898-4
Long GV et al (2017a) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28:1631–1639. https://doi.org/10.1093/annonc/mdx176
Long GV et al (2017b) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823. https://doi.org/10.1056/NEJMoa1708539
Luke JJ, Schwartz GK (2013) Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol 31:290–297. https://doi.org/10.1016/j.clindermatol.2012.08.016
Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621. https://doi.org/10.1634/theoncologist.12-5-610
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: Part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 72:221–236; quiz 237–228. https://doi.org/10.1016/j.jaad.2014.07.033
Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS (2018) Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.05.035
Minor DR, Rodvien R, Kashani-Sabet M (2012) Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res 22:410–411. https://doi.org/10.1097/CMR.0b013e3283573437
Mochel MC et al (2016) Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol 43:787–791. https://doi.org/10.1111/cup.12735
Naidoo J et al (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4:383–389. https://doi.org/10.1158/2326-6066.CIR-15-0123
Nayar N, Briscoe K, Fernandez Penas P (2016) Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother 39:149–152. https://doi.org/10.1097/CJI.0000000000000112
Palathinkal DM, Sharma TR, Koon HB, Bordeaux JS (2014) Current systemic therapies for melanoma. Dermatol Surg 40:948–963. https://doi.org/10.1097/01.DSS.0000452626.09513.55
Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC (2014) Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol 150:307–311. https://doi.org/10.1001/jamadermatol.2013.7919
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S (2018) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2:CD011123. https://doi.org/10.1002/14651858.CD011123.pub2
Pattanaprichakul P et al (2014) Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol 41:326–328. https://doi.org/10.1111/cup.12273
Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, Lacouture ME (2018) Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatol. https://doi.org/10.1001/jamadermatol.2018.4560
Robert C et al (2015a) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093
Robert C et al (2015b) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. https://doi.org/10.1056/NEJMoa1412690
Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, Baran R (2015c) Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16:e181–e189. https://doi.org/10.1016/S1470-2045(14)71133-7
Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327–333. https://doi.org/10.1007/s40257-013-0021-0
Sanlorenzo M et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206–1212. https://doi.org/10.1001/jamadermatol.2015.1916
Schad K, Baumann Conzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, Dummer R (2010) Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 16:1058–1064. https://doi.org/10.1158/1078-0432.CCR-09-1766
Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19:345–361. https://doi.org/10.1007/s40257-017-0336-3
Sibaud V et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26:427–443. https://doi.org/10.1684/ejd.2016.2833
Siegel J et al (2018) Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.07.008
Su F et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215. https://doi.org/10.1056/NEJMoa1105358
Tetzlaff MT et al (2017) Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol 39:121–129. https://doi.org/10.1097/DAD.0000000000000688
Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773–781. https://doi.org/10.1200/JCO.2014.57.4756
Treudler R, Georgieva J, Geilen CC, Orfanos CE (2004) Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol 50:783–785. https://doi.org/10.1016/j.jaad.2003.12.016
Uenami T et al (2017) Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer 109:42–44. https://doi.org/10.1016/j.lungcan.2017.04.019
Vazquez-Osorio I, Sanchez-Aguilar MD, Garcia-Rodino S, Suarez-Penaranda JM, Aliste C, Vazquez-Veiga H (2016) Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature. Am J Dermatopathol 38:e93–e96. https://doi.org/10.1097/DAD.0000000000000528
Wang LL et al (2018) Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 154: 1057–1061. https://doi.org/10.1001/jamadermatol.2018.1912
Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691–2697. https://doi.org/10.1200/JCO.2012.41.6750
Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS (2013) Vemurafenib-induced DRESS. JAMA Dermatol 149:1242–1243. https://doi.org/10.1001/jamadermatol.2013.5278
Wollina U (2001) Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 15:82–84
Yin ES, Totonchy MB, Leventhal JS (2017) Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep 3:90–92. https://doi.org/10.1016/j.jdcr.2016.10.008
Yorio JT et al (2014) Case of vemurafenib-induced Sweet’s syndrome. J Dermatol 41:817–820. https://doi.org/10.1111/1346-8138.12430
Yung CW, Winston EM, Lorincz AL (1981) Dacarbazine-induced photosensitivity reaction. J Am Acad Dermatol 4:541–543
Zimmer L et al (2012a) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375–2383. https://doi.org/10.1200/JCO.2011.41.1660
Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, Schadendorf D (2012b) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148:357–361. https://doi.org/10.1001/archdermatol.2011.2842
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Menzer, C., Chen, S.T., Phillips, G.S., Lacouture, M.E. (2019). Cutaneous Adverse Events of Systemic Melanoma Treatments. In: Fisher, D., Bastian, B. (eds) Melanoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7147-9_38
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7147-9_38
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7148-6
Online ISBN: 978-1-4614-7147-9
eBook Packages: MedicineReference Module Medicine